Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021
Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Specific allergen immunotherapy of asthma combined with allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
Evaluation of six-year allergen immunotherapy in allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012
Evaluation and efficacy of allergen immunotherapy in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 399s Year: 2005
Specific immunotherapy in the management of allergic asthma Source: Annual Congress 2008 - PG2 - Asthma: natural history, risk factors and overall management Year: 2008
Effect of allergen-specific immunotherapy on platelet secretory activity in patients with house-dust mite allergy Source: Eur Respir J 2007; 30: Suppl. 51, 369s Year: 2007
Efficacy and safety of 300IR 5-grass pollen sublingual tablet in allergic patients with and without asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Sublingual monomeric allergoid immunotherapy improves airway inflammation, airway hyperresponsiveness and clinical symptoms in allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006
Specific immunotherapy in grass-pollen allergic asthma combinated with inhaled steroid therapy vs specific immunotherapy allone Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001
Efficacy of ruzam in the treatment of patients with perennial allergic rhinitis Source: Eur Respir J 2004; 24: Suppl. 48, 131s Year: 2004